Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab Safety in AMD (RATE)
NCT01319188Phase 4Terminated
- Sponsor
- Ural State Medical University
- Start
- Jun 2010
- Primary completion
- Oct 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of ranibizumab in age-related macular degeneration (AMD) (3 arms), sponsored by Ural State Medical University. Primary endpoint: Arterial thromboembolic events rate at 24 months. Started Jun 2010; status: terminated.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT01319188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01319188.